http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<!-- InstanceBegin template="/Templates/phac-aspc-2col-php-eng.dwt.php" codeOutsideHTMLIsLocked="false" -->
<head>
<!-- CLF 2.0 TEMPLATE VERSION 1.04 | VERSION 1.04 DU GABARIT NSI 2.0 -->
<!-- HEADER BEGINS | DEBUT DE L'EN-TETE -->
<!-- InstanceBeginEditable name="meta" -->
<!-- InstanceEndEditable -->
<!-- TITLE BEGINS | DEBUT DU TITRE -->
<!-- InstanceBeginEditable name="doctitle" -->
<title>Ebolavirus - Pathogen Safety Data Sheets</title>
<!-- InstanceEndEditable -->
<!-- TITLE ENDS | FIN DU TITRE -->
<!--[if IE]>
	<link href="/css/institution-ie.css" media="screen, print" rel="stylesheet" type="text/css" />
<![endif]-->


<!--[if IE 7]>
	<style type="text/css">
		div.center sup a.footnote-link{;
			background-color: #EEEEEE;
			border: 1px solid #CCCCCC;
			display: inline!important;
			font-size:100%!important;
			padding: 0 2px;
			line-height:1.2em;
	}
	</style>
<![endif]-->

<!--[if gte IE 8]>
	<style type="text/css">
		div.center sup a.footnote-link{;
			background-color: #EEEEEE;
			border: 1px solid #CCCCCC;
			display: inline-block!important;
			font-size:150%!important;
			padding: 1px 2px 4px 2px;
			line-height:1.2em;
	}
	</style>
<![endif]-->

<!--[if !IE]><!-->
	<style type="text/css">
		div.center sup a.footnote-link{;
			background-color: #EEEEEE;
			border: 1px solid #CCCCCC;
			display: inline!important;
			padding: 0 2px 1px 2px;
			line-height:1.2em;
	}
	</style>
<!--<![endif]-->


<!-- METADATA BEGINS | DEBUT DES METADONNEES -->
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1" />
<link rel="schema.dc" href="http://purl.org/dc/elements/1.1/" />
<link rel="schema.dcterms" href="http://purl.org/dc/terms/" />
<meta name="dc.description" content="Pathogen Safety Data Sheets, regulated under Workplace Hazardous Materials Information System (WHMIS) legislation, for chemical products have been available to workers for many years. However because many laboratory workers, whether in research, public health, teaching, etc., are exposed to not only chemicals but infectious substances as well, there was a large gap in the readily available safety literature for employees. These MSDS are produced for personnel working in the life sciences as quick safety reference material relating to infectious micro-organisms" />
<meta name="Description" content="Pathogen Safety Data Sheets, regulated under Workplace Hazardous Materials Information System (WHMIS) legislation, for chemical products have been available to workers for many years. However because many laboratory workers, whether in research, public health, teaching, etc., are exposed to not only chemicals but infectious substances as well, there was a large gap in the readily available safety literature for employees. These MSDS are produced for personnel working in the life sciences as quick safety reference material relating to infectious micro-organisms." />
<meta name="Keywords" content="Pathogen Safety Data Sheets, PSDS, Infectious Substances, Health Canada, chemical, infection, micro-organisms" />
<meta name="dc.creator" content="Government of Canada, Public Health Agency of Canada" />
<meta name="dc.title" content="Ebolavirus - Pathogen Safety Data Sheets" />
<meta name="dcterms.issued" scheme="W3CDTF" content="2001-09-17" />
<meta name="dcterms.modified" scheme="W3CDTF" content="2014-08-22" />
<meta name="dc.subject" scheme="gchccv" content="Emergency Preparedness" />
<meta name="dc.language" scheme="ISO639-2/T" content="eng" />
<!-- METADATA ENDS | FIN DES METADONNEES -->
<!-- PHAC-ASPC site wide Google Analytics Code Start -->
<script type="text/javascript" src="/includes/analytics-analytique/jquery144/jquery.min.js"></script>
<script type="text/javascript" src="/includes/analytics-analytique/ga-addon.js"></script>
<script type="text/javascript">

  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-8551263-1'],
  ['_gat._anonymizeIp'],
  ['_setDomainName', 'none'],
  ['_trackPageview'],
  ['_trackDownload'],
  ['_trackOutbound']
 	);   

  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();

</script>
<!-- PHAC-ASPC site wide Google Analytics Code End -->

<script src="/scripts/jqueryui/1.8.11/jquery-ui.min.js" type="text/javascript"></script>
<script src="/scripts/jquery.tablesorter.min.js" type="text/javascript"></script>
<!-- TEMPLATE SCRIPTS/CSS BEGIN | DEBUT DES SCRIPTS/CSS DU GABARIT -->
<link href="../../../css/base.css" media="screen, print" rel="stylesheet" type="text/css" />
<link href="../../../css/2col.css" media="screen, print" rel="stylesheet" type="text/css" />
<style type="text/css" media="all">
@import url(../../../css/base2.css);
</style>
<!-- TEMPLATE SCRIPTS/CSS END | FIN DES SCRIPTS/CSS DU GABARIT -->
<!-- PROGRESSIVE ENHANCEMENT BEGINS | DEBUT DE L'AMELIORATION PROGRESSIVE -->
<script src="../../../scripts/pe-ap.js" type="text/javascript"></script>
<script src="../../../scripts/leaf-eng.js" type="text/javascript"></script>
<script src="../../../scripts/siteWide.js" type="text/javascript"></script>
<!-- PROGRESSIVE ENHANCEMENT ENDS | FIN DE L'AMELIORATION PROGRESSIVE -->
<!-- CUSTOM SCRIPTS/CSS BEGIN | DEBUT DES SCRIPTS/CSS PERSONNALISES -->
<link href="../../../css/base-institution.css" media="screen, print" rel="stylesheet" type="text/css" />
<link href="../../../css/institution.css" media="screen, print" rel="stylesheet" type="text/css" />
<!-- CUSTOM SCRIPTS/CSS END | FIN DES SCRIPTS/CSS PERSONNALISES -->
<!-- TEMPLATE PRINT CSS BEGINS | DEBUT DU CSS DU GABARIT POUR L'IMPRESSION -->
<link href="../../../css/pf-if.css" rel="stylesheet" type="text/css" />
<!-- TEMPLATE PRINT CSS ENDS | FIN DU CSS DU GABARIT POUR L'IMPRESSION -->
<!-- InstanceBeginEditable name="scripts" -->
<!-- InstanceEndEditable -->
</head>
<body>
<div class="page">
  <div class="core">
      <!-- FIP HEADER BEGINS | DEBUT DE L'EN-TETE PCIM -->
  <div class="fip"><a name="tphp" id="tphp"><img src="/images/sig-eng.gif" width="372" height="22" alt="Public Health Agency of Canada" /></a></div>
  <div class="cwm"><img src="/images/wmms.gif" width="83" height="20" alt="Symbol of the Government of Canada" /></div>
  <!-- FIP HEADER ENDS | FIN DE L'EN-TETE PCIM -->
  <!-- INSTITUTIONAL BANNER STARTS | DEBUT DE LA BANNIERE INSTITUTIONNELLE -->
  <div class="banner"> <img src="/images/lffl.gif" class="lf pngfix" height="65" width="65" alt="" />
   <p class="main">Public Health Agency of Canada</p>
   <p class="siteuri">www.publichealth.gc.ca</p>
  </div>
  <!-- INSTITUTIONAL BANNER ENDS | FIN DE LA BANNIERE INSTITUTIONNELLE -->
  <!-- SKIP NAVIGATION BEGINS | DEBUT DU SAUT DE NAVIGATION -->
  <div class="navaid"> <a href="#cont">Skip to content</a> | <a href="#il">Skip to institutional links</a> </div>
  <!-- SKIP NAVIGATION ENDS | FIN DU SAUT DE NAVIGATION -->
  <!-- COMMON MENU BAR BEGINS | DEBUT DE LA BARRE DE MENU COMMUNE -->
  <div class="fp">
   <!-- COMMON MENU BAR TITLE BEGINS | DEBUT DU TITRE DE LA BARRE DE MENU COMMUNE -->
   <p class="navaid">Common menu bar links</p>
   <!-- COMMON MENU BAR TITLE ENDS | FIN DU TITRE DE LA BARRE DE MENU COMMUNE -->
   <ul class="commonbar">
    <!-- FRENCH LINK BEGINS | DEBUT DU LIEN FRANCAIS -->
    <li class="fiptexta">
     <div><!-- TemplateBeginEditable name="lang" --><a href="ebola-fra.php" lang="fr" xml:lang="fr" title="Fran&ccedil;ais - Version fran&ccedil;aise de cette page">Fran&ccedil;ais</a><!-- TemplateEndEditable --></div>
    </li>
    <!-- FRENCH LINK ENDS | FIN DU LIEN FRANCAIS -->
    <li class="fiptext">
     <div><a href="/index-eng.php" title="Home - The main page of PHAC's Web site">Home</a></div>
    </li>
    <li class="fiptextc">
     <div><a href="/contac-eng.php" title="Contact Us - PHAC contact information">Contact Us</a></div>
    </li>
    <li class="fiptext">
     <div><a href="/help-aide-eng.php" title="Help - Information about using the PHAC Web site">Help</a></div>
    </li>
    <li class="fiptext">
     <div><a href="/recherche-search-eng.php" title="Search - Search the PHAC Web site">Search</a></div>
	 </li>
    <li class="fiptextb"><div><a href="http://www.canada.ca/en/index.html" title="Canada.ca - Government of Canada Web site">Canada.ca</a></div>
	</li>
   </ul>
  </div>
	
  <!-- COMMON MENU BAR ENDS | FIN DE LA BARRE DE MENU COMMUNE -->
  <!-- HEADER ENDS | FIN DE L'EN-TETE -->    <!-- BREAD CRUMB BEGINS | DEBUT DE LA PISTE DE NAVIGATION -->
    <p class="breadcrumb"><!-- InstanceBeginEditable name="crumbs" -->
        <a href="/index-eng.php">Home</a> &gt;
  <a href="/lab-bio/index-eng.php">Laboratory Biosafety and Biosecurity</a> &gt;
  <a href="/lab-bio/res/psds-ftss/index-eng.php">Pathogen Safety Data Sheets and Risk Assessment</a> &gt;       Ebolavirus<!-- InstanceEndEditable --></p>
    <!-- BREAD CRUMB ENDS | FIN DE LA PISTE DE NAVIGATION -->
    <div class="colLayout">
      <!-- TWO COLUMN LAYOUT BEGINS | DEBUT DE LA MISE EN PAGE DE DEUX COLONNES -->
      <!-- LEFT SIDE MENU BEGINS | DEBUT DU MENU LATERAL GAUCHE -->
      <div class="left"><!-- InstanceBeginEditable name="leftnav" -->
        <!-- START PHAC-ASPC LEFT NAVIGATION | DEBUT DE LA NAVIGATION GAUCHE PHAC-ASPC -->
<!-- SIDE MENU TITLE BEGINS | DEBUT DU TITRE DU MENU LATERAL -->

<h1 class="navaid"><a name="il" id="il">Institutional links</a></h1>
<!-- SIDE MENU TITLE ENDS | FIN DU TITRE DU MENU LATERAL -->
<ul class="nav">
	<li>
		<h2 class="nav rounded">Main Menu</h2>
		<ul class="nav">
			<li class="menucontent divider"><a class="menulink" href="/about_apropos/index-eng.php" title="About the Agency">About the Agency</a></li>
			<li class="menucontent"><a class="menulink" href="/id-mi/index-eng.php">Infectious Diseases</a></li>
			<li class="menucontent divider"><a class="menulink" href="/cd-mc/index-eng.php">Chronic Diseases</a></li>
			<li class="menucontent"><a class="menulink" href="/tmp-pmv/index-eng.php" title="Travel Health">Travel Health</a></li>
			<li class="menucontent"><a class="menulink" href="/fs-sa/index-eng.php" title="Food Safety">Food Safety</a></li>
			<li class="menucontent"><a class="menulink" href="/im/index-eng.php" title="Immunization &amp; Vaccines">Immunization &amp; Vaccines</a></li>
			<li class="menucontent divider"><a class="menulink" href="/ep-mu/index-eng.php" title="Emergency Preparedness &amp; Response">Emergency Preparedness &amp; Response</a></li>
			<li class="menucontent"><a class="menulink" href="/hp-ps/index-eng.php" title="Health Promotion">Health Promotion</a></li>
			<li class="menucontent divider"><a class="menulink" href="/inj-bles/index-eng.php" title="Injury Prevention">Injury Prevention</a></li>
			<li class="menucontent divider"><a class="menulink" href="/lab-bio/index-eng.php" title="Lab Biosafety &amp; Biosecurity">Lab Biosafety &amp; Biosecurity</a></li>
			<li class="menucontent"><a class="menulink" href="/surveillance-eng.php" title="Surveillance">Surveillance</a></li>
		</ul>
	</li>
	<li>
		<h2 class="nav">Explore</h2>
		<ul class="nav">
			<li class="menucontent"><a class="menulink" href="/media/index-eng.php" title="Media Room">Media Room</a></li>
			<li class="menucontent"><a class="menulink" href="/about_apropos/act-reg-lois/index-eng.php" title="Acts &amp; Regulations">Acts &amp; Regulations</a></li>
			<li class="menucontent"><a class="menulink" href="/publications-eng.php" title="Reports &amp; Publications">Reports &amp; Publications</a></li>
			<li class="menucontent"><a class="menulink" href="/a-z/index-eng.php" title="A-Z Index">A-Z Index</a></li>
		</ul>
	</li>
	<li>
		<h2 class="nav">Transparency</h2>
		<ul class="nav">
			<li class="menucontent"><a class="menulink" href="/about_apropos/eab-oce/index-eng.php" title="External Advisory Bodies">External Advisory Bodies</a></li>
			<li class="menucontent"><a class="menulink" href="/about_apropos/engagement-participation/index-eng.php" title="Public Engagement">Public Engagement</a></li>
			<li class="menucontent"><a class="menulink" href="/about_apropos/atip-aiprp/request-demande/index-eng.php" title="Completed Access to Information Requests">Completed Access to Information Requests</a></li>
			<li class="menucontent"><a class="menulink" href="/pd-dp/index-eng.php">Proactive Disclosure</a></li>
		</ul>
	</li>
</ul>
<!-- END PHAC-ASPC LEFT NAVIGATION | FIN DE LA NAVIGATION GAUCHE PHAC-ASPC -->
        <!-- InstanceEndEditable --></div>
      <!-- LEFT SIDE MENU ENDS | FIN DU MENU LATERAL GAUCHE -->
      <!-- CONTENT BEGINS | DEBUT DU CONTENU -->
      <div class="center"><!-- InstanceBeginEditable name="content" -->
        
<!-- ########################################### -->
<!-- START Page Tools | DEBUT des outils de page -->
<div id="PageTools">
	<ul>
		<li><div class="Icons-FontSizerButton"><a href="/text-texte-eng.php" onclick="toggleTextSize(); return false;">+/- Text</a></div></li>
        <li id="shareButton"><div class="Icons-ShareButton"><a href="/lab-bio/res/psds-ftss/ebola-eng.php?option=share" onclick="toggleShare();return false;">Share</a></div></li>
	</ul>
</div>
<script type="text/javascript">
//<![CDATA[
   $('<li><div class="Icons-PrintButton"><a href="/lab-bio/res/psds-ftss/ebola-eng.php?option=print"  onclick="javascript:window.print(); return false;">Print<\/a><\/div><\/li>').insertBefore('#shareButton');
//]]>
</script>
<script type="text/javascript">
	function toggleShare() {
		var class_name = document.getElementById('ShareContainer').className;
		document.getElementById('ShareContainer').className = (class_name == 'HiddenElement') ? '' : 'HiddenElement' ;
	}
</script>
<!-- END Page Tools | FIN des outils de page -->
<!-- ####################################### -->

<!-- ########################################################################### -->
<!-- START Share content container | DEBUT du conteneur pour Envoyez cette page -->
<div id="ShareContainer" class="HiddenElement">
	<div id="SharePage">
		<div id="ShareContent" class="ExBox-Container-487795">
		<!-- START expandable header | DEBUT de l'en-tête extensible -->
			<div class="ExBox-Header-487795">
				<div class="ExBox-Header-Outer-487795">
					<div class="ExBox-Header-Inner-487795"><h2>Share this page</h2></div>
				</div>
			</div>

			<!-- END expandable header | FIN de l'en-tête extensible -->
			<!-- START expandable content | DEBUT du contenu extensible -->
			<div id="sharelinks" class="ExBox-Content-487795">
				<div id="social">
	                <p>To share this page just click on the social network icon of your choice.</p>
    				<div class="row">
                    <div class="colWidth50">
    				<ul>
						<li><img src="/media/social/images/twitter.png" alt="Twitter" /><a href="http://twitter.com/home?status=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">Twitter</a></li>
<li><img src="/media/social/images/facebook.png" alt="Facebook" /><a href="http://www.facebook.com/sharer.php?u=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">Facebook</a></li>
<li><img src="/media/social/images/delicious.png" alt="Delicious" /><a href="http://delicious.com/post?url=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">Delicious</a></li>
<li><img src="/media/social/images/google.png" alt="GOOGLE" /><a href="http://www.google.com/bookmarks/mark?op=edit&amp;output=popup&amp;bkmk=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">Google</a></li>
<li><img src="/media/social/images/technorati.png" alt="TECHNORATI FAVORITES"/><a href="http://technorati.com/faves?add=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets" >Technorati</a></li>
            		</ul>
                    </div>
                    <div class="colWidth50">
                    <ul>
						<li><img src="/media/social/images/digg.png" alt="DIGG" /><a href="http://digg.com/submit?phase=2&amp;url=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">Digg</a></li>
<li><img src="/media/social/images/stumble1.gif" alt="STUMBLEUPON" /><a href="http://www.stumbleupon.com/submit?url=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets">StumbleUpon</a></li>
<li><img src="/media/social/images/reddit.gif" alt="REDDIT" /><a href="http://reddit.com/submit?url=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets" >Reddit</a></li>
<li><img src="/media/social/images/yahoo.png" alt="YAHOO MYWEB" /><a href="http://bookmarks.yahoo.com/myresults/bookmarklet?u=http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php&amp;title=Ebolavirus+-+Pathogen+Safety+Data+Sheets" >Yahoo MyWeb</a></li>            		</ul>
                    </div>
                    </div>
                    <span class="spacer">&nbsp;</span>
				</div>
			</div>
			<!-- END expandable content | FIN du contenu extensible -->

			<!-- START footer | DEBUT le bas de la boîte -->
			<div class="ExBox-Footer-487795">
				<div class="ExBox-Footer-Outer-487795">
					<div class="Icons-MoreLink"><a href="/lab-bio/res/psds-ftss/ebola-eng.php" onclick="toggleShare();return false;">Close</a></div>
				</div>
			</div>
			<!-- END footer | FIN le bas de la boîte -->
		</div>
	</div>
</div>

<!-- END E-mail content container | FIN du conteneur pour Envoyez cette page -->
<!-- ####################################################################### -->





    
<div class="navaid"><a name="cont" id="cont"></a></div>
        <h1>EBOLAVIRUS</h1>
        <p class="border-solid padding10px bg-colour-yellow">For more information about Ebola, visit <a href="/id-mi/vhf-fvh/ebola-eng.php?phac_source=ebola_14&amp;medium=in_page_link&amp;content=pathogen_safety_data_sheet_en&amp;campaign=ebola">Ebola Virus Disease</a></p>
        <h2>PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES</h2>
        <h3>SECTION I - INFECTIOUS AGENT</h3>
        <p><strong>NAME</strong>: Ebolavirus</p>
        <p><strong>SYNONYM OR CROSS REFERENCE</strong>: African haemorrhagic fever, Ebola haemorrhagic fever (EHF, Ebola HF), filovirus, EBO virus (EBOV), Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV, SUDV), Ivory Coast ebolavirus (ICEBOV), Tai Forest ebolavirus (TAFV), Ebola-Reston (REBOV, EBO-R, Reston Virus, RESTV), Bundibugyo ebolavirus (BEBOV, BDBV), and Ebola virus disease (EVD) <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote3" class="footnote-link"><span class="hiddentext">Footnote </span>3</a></sup>&nbsp;<sup><a href="#footnote4" class="footnote-link"><span class="hiddentext">Footnote </span>4</a></sup>.</p>
        <p><strong>CHARACTERISTICS</strong>: Ebola was discovered in 1976 and is a member of the Filoviridae family (previously part of Rhabdoviridae family, which were later given a family of their own based on their genetic structure). Five Ebola species have been identified: Zaire ebolavirus (ZEBOV), which was first identified in 1976 and is the most virulent; Sudan ebolavirus, (SEBOV); Tai Forest ebolavirus (formerly Ivory Coast ebolavirus); Ebola-Reston (REBOV), originating from the Philippines; and Bundibugyo ebolavirus (BEBOV), the most recent species discovered (2008) <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote3" class="footnote-link"><span class="hiddentext">Footnote </span>3</a></sup>&nbsp;<sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>&nbsp;<sup><a href="#footnote6" class="footnote-link"><span class="hiddentext">Footnote </span>6</a></sup>&nbsp;<sup><a href="#footnote7" class="footnote-link"><span class="hiddentext">Footnote </span>7</a></sup>.<br />
          <br />
          Ebola is an elongated filamentous virus, which can vary between 800 - 1000 nm in length, and can reach up to 14000 nm long (due to concatamerization) with a uniform diameter of 80 nm <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>&nbsp;<sup><a href="#footnote8" class="footnote-link"><span class="hiddentext">Footnote </span>8</a></sup>&nbsp;<sup><a href="#footnote9" class="footnote-link"><span class="hiddentext">Footnote </span>9</a></sup>. It contains a helical nucleocapsid (with a central axis), 20 - 30 nm in diameter, and is enveloped by a helical capsid, 40 - 50 nm in diameter, with 5 nm cross-striations <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>&nbsp;<sup><a href="#footnote8" class="footnote-link"><span class="hiddentext">Footnote </span>8</a></sup>&nbsp;<sup><a href="#footnote9" class="footnote-link"><span class="hiddentext">Footnote </span>9</a></sup>&nbsp;<sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup>. The pleomorphic viral fragment may take on several distinct shapes (e.g., in the shape of a &quot;6&quot;, a &quot;U&quot;, or a circle), and are contained within a lipid membrane <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>. Each virion contains a single-strand of non-segmented, negative-sense viral genomic RNA <sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>&nbsp;<sup><a href="#footnote11" class="footnote-link"><span class="hiddentext">Footnote </span>11</a></sup>.</p>
        <h3>SECTION II - HAZARD IDENTIFICATION</h3>
        <p><strong>PATHOGENICITY/TOXICITY</strong>: Ebola virions enter host cells through endocytosis and replication occurs in the cytoplasm. Upon infection, the virus affects the host blood coagulative and immune defence system and leads to severe immunosuppression <sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup>&nbsp;<sup><a href="#footnote12" class="footnote-link"><span class="hiddentext">Footnote </span>12</a></sup>. Early signs of infection are non-specific and flu-like, and may include sudden onset of fever, asthenia, diarrhea, headache, myalgia, arthralgia, vomiting, and abdominal pains <sup><a href="#footnote13" class="footnote-link"><span class="hiddentext">Footnote </span>13</a></sup>. Less common early symptoms include conjunctival injection, sore throat, rashes, and bleeding. Shock, cerebral oedema, coagulation disorders, and secondary bacterial infection may co-occur later in infection <sup><a href="#footnote8" class="footnote-link"><span class="hiddentext">Footnote </span>8</a></sup>. Haemorrhagic symptoms may begin 4 - 5 days after onset, including hemorrhagic conjunctivitis, pharyngitis, bleeding gums, oral/lip ulceration, hematemesis, melena, hematuria, epistaxis, and vaginal bleeding <sup><a href="#footnote14" class="footnote-link"><span class="hiddentext">Footnote </span>14</a></sup>. Hepatocellular damage, marrow suppression (such as thrombocytopenia and leucopenia), serum transaminase elevation, and proteinuria may also occur. Persons that are terminally ill typically present with obtundation, anuria, shock, tachypnea, normothermia to hypothermia, arthralgia, and ocular diseases <sup><a href="#footnote15" class="footnote-link"><span class="hiddentext">Footnote </span>15</a></sup>. Haemorrhagic diathesis is often accompanied by hepatic damage and renal failure, central nervous system involvement, and terminal shock with multi-organ failure <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>. Contact with the virus may also result in symptoms such as severe acute viral illness, malaise, and maculopapular rash. Pregnant women will usually abort their foetuses and experience copious bleeding <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote16" class="footnote-link"><span class="hiddentext">Footnote </span>16</a></sup>. Fatality rates range between 50 - 100%, with most dying of hypovolemic shock and multisystem organ failure <sup><a href="#footnote17" class="footnote-link"><span class="hiddentext">Footnote </span>17</a></sup>.</p>
        <p>Pathogenicity between species of Ebola does not differ greatly in that they have all been associated with hemorrhagic fever outbreaks in humans (excluding Reston) and non-human primates. The Ebola-Zaire and Sudan strains are especially known for their virulence with up to 90% fatality rate <sup><a href="#footnote18" class="footnote-link"><span class="hiddentext">Footnote </span>18</a></sup>, with reduced virulence noted in the Tai Forest ebolavirus and the more recently discovered Bundibugyo strain, which caused a single outbreak in Uganda <sup><a href="#footnote6" class="footnote-link"><span class="hiddentext">Footnote </span>6</a></sup>&nbsp;<sup><a href="#footnote7" class="footnote-link"><span class="hiddentext">Footnote </span>7</a></sup>. Bundibugyo was the outbreak virus in Isiro, Democratic Republic of Congo, in 2012. Ebola-Reston was isolated from cynomolgus monkeys from the Philippines in 1989 and is less pathogenic in non-human primates. Ebola-Reston virus appears to be non-pathogenic in humans, with reported health effects limited to serological evidence of exposure as identified in 4 animal handlers working with infected non-human primates <sup><a href="#footnote19" class="footnote-link"><span class="hiddentext">Footnote </span>19</a></sup>.</p>
        <p><strong>EPIDEMIOLOGY</strong>: Occurs mainly in areas surrounding rain forests in equatorial Africa <sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup> with the exception of Reston, which has been documented to originate in the Philippines <sup><a href="#footnote7" class="footnote-link"><span class="hiddentext">Footnote </span>7</a></sup>. No predispositions to infection have been identified among infected persons.</p>
        <p>The largest recorded ebolavirus outbreak to date began in March 2014, with initial cases reported in Guinea and then additional cases identified in the surrounding regions (Liberia, Sierra Leone, Nigeria). A new strain of the ZEBOV species was identified as the causative agent of the outbreak <sup><a href="#footnote16" class="footnote-link"><span class="hiddentext">Footnote </span>16</a></sup>&nbsp;<sup><a href="#footnote21" class="footnote-link"><span class="hiddentext">Footnote </span>21</a></sup>&nbsp;<sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>.</p>
        <p><strong>HOST RANGE</strong>: Humans, various monkey species, chimpanzees, gorillas, baboons, and duikers are natural animal hosts for ebolavirus <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote5" class="footnote-link"><span class="hiddentext">Footnote </span>5</a></sup>&nbsp;<sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>&nbsp;<sup><a href="#footnote23" class="footnote-link"><span class="hiddentext">Footnote </span>23</a></sup>&nbsp;<sup><a href="#footnote24" class="footnote-link"><span class="hiddentext">Footnote </span>24</a></sup>&nbsp;<sup><a href="#footnote25" class="footnote-link"><span class="hiddentext">Footnote </span>25</a></sup>&nbsp;<sup><a href="#footnote26" class="footnote-link"><span class="hiddentext">Footnote </span>26</a></sup>&nbsp;<sup><a href="#footnote27" class="footnote-link"><span class="hiddentext">Footnote </span>27</a></sup>&nbsp;<sup><a href="#footnote28" class="footnote-link"><span class="hiddentext">Footnote </span>28</a></sup>&nbsp;<sup><a href="#footnote29" class="footnote-link"><span class="hiddentext">Footnote </span>29</a></sup>&nbsp;<sup><a href="#footnote30" class="footnote-link"><span class="hiddentext">Footnote </span>30</a></sup>&nbsp;<sup><a href="#footnote31" class="footnote-link"><span class="hiddentext">Footnote </span>31</a></sup>. Serological evidence of immunity markers to ebolavirus in serum collected from domesticated dogs suggests asymptomatic infection is plausible, likely following exposure to infected humans or animal carrion <sup><a href="#footnote32" class="footnote-link"><span class="hiddentext">Footnote </span>32</a></sup>&nbsp;<sup><a href="#footnote33" class="footnote-link"><span class="hiddentext">Footnote </span>33</a></sup>. The Ebolavirus genome was discovered in two species of rodents and one species of shrew living in forest border areas, raising the possibility that these animals may be intermediary hosts <sup><a href="#footnote34" class="footnote-link"><span class="hiddentext">Footnote </span>34</a></sup>. Experimental studies of the virus have been done using mouse, pig, guinea pig, and hamster models, suggesting wild-type ebolavirus has limited pathogenicity in these models <sup><a href="#footnote35" class="footnote-link"><span class="hiddentext">Footnote </span>35</a></sup>&nbsp;<sup><a href="#footnote36" class="footnote-link"><span class="hiddentext">Footnote </span>36</a></sup>.</p>
        <p>Bats are considered to be a plausible reservoir for the virus. Serological evidence of infection with ebolavirus (antibody detection to EBOV, ZEBOV, and/or REBOV) has been reported in fruit bats collected from woodland and forested areas near Ghana and Gabon, with reduced frequency of isolation from bats collected in mainland China and Bangladesh <sup><a href="#footnote37" class="footnote-link"><span class="hiddentext">Footnote </span>37</a></sup>&nbsp;<sup><a href="#footnote38" class="footnote-link"><span class="hiddentext">Footnote </span>38</a></sup>&nbsp;<sup><a href="#footnote39" class="footnote-link"><span class="hiddentext">Footnote </span>39</a></sup>&nbsp;<sup><a href="#footnote40" class="footnote-link"><span class="hiddentext">Footnote </span>40</a></sup>.</p>
        <p><strong>INFECTIOUS DOSE</strong>: Viral hemorrhagic fevers have an infectious dose of 1 - 10 organisms by aerosol in non-human primates <sup><a href="#footnote41" class="footnote-link"><span class="hiddentext">Footnote </span>41</a></sup>.</p>
        <p><strong>MODE OF TRANSMISSION</strong>: In an outbreak, it is hypothesized that the first patient becomes infected as a result of contact with an infected animal <sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>. Person-to-person transmission occurs via close personal contact with an infected individual or their body fluids during the late stages of infection or after death <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>&nbsp;<sup><a href="#footnote42" class="footnote-link"><span class="hiddentext">Footnote </span>42</a></sup>. Nosocomial infections can occur through contact with infected body fluids for example due to the reuse of unsterilized syringes, needles, or other medical equipment contaminated with these fluids <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>. Humans may be infected by handling sick or dead non-human primates and are also at risk when handling the bodies of deceased humans in preparation for funerals <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup>&nbsp;<sup><a href="#footnote43" class="footnote-link"><span class="hiddentext">Footnote </span>43</a></sup>.</p>
        <p>In laboratory settings, non-human primates exposed to aerosolized ebolavirus from  pigs have become infected, however, airborne  transmission has not been demonstrated between non-human primates <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span> 1</a></sup>&nbsp;<sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup>&nbsp;<sup><a href="#footnote15" class="footnote-link"><span class="hiddentext">Footnote </span>15</a></sup>&nbsp;<sup><a href="#footnote44" class="footnote-link"><span class="hiddentext">Footnote </span>44</a></sup>&nbsp;<sup><a href="#footnote45" class="footnote-link"><span class="hiddentext">Footnote </span>45</a></sup>. Viral shedding has been observed in nasopharyngeal secretions and rectal swabs of pigs following experimental inoculation <sup><a href="#footnote29" class="footnote-link"><span class="hiddentext">Footnote </span>29</a></sup>&nbsp;<sup><a href="#footnote30" class="footnote-link"><span class="hiddentext">Footnote </span>30</a></sup>.</p>
        <p><strong>INCUBATION PERIOD</strong>: Two to 21 days <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote15" class="footnote-link"><span class="hiddentext">Footnote </span>15</a></sup>&nbsp;<sup><a href="#footnote17" class="footnote-link"><span class="hiddentext">Footnote </span>17</a></sup>.</p>
        <p><strong>COMMUNICABILITY</strong>: Communicable  as long as blood,  body fluids or organs,   contain the virus. Ebolavirus has been isolated from semen  61 to 82 days after the onset of illness, and transmission through semen has  occurred 7 weeks after clinical recovery <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote59" class="footnote-link"><span class="hiddentext">Footnote </span>59</a></sup> <sup><a href="#footnote60" class="footnote-link"><span class="hiddentext">Footnote </span>60</a></sup>.</p>
        <h3>SECTION III - DISSEMINATION</h3>
        <p><strong>RESERVOIR</strong>: The natural reservoir of Ebola is unknown <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>. Antibodies to the virus have been found in the serum of domestic guinea pigs and wild rodents, with no relation to human transmission <sup><a href="#footnote34" class="footnote-link"><span class="hiddentext">Footnote </span>34</a></sup>&nbsp;<sup><a href="#footnote47" class="footnote-link"><span class="hiddentext">Footnote </span>47</a></sup>. Serum antibodies and viral RNA have been identified in some bat species, suggesting bats may be a natural reservoir <sup><a href="#footnote37" class="footnote-link"><span class="hiddentext">Footnote </span>37</a></sup>&nbsp;<sup><a href="#footnote38" class="footnote-link"><span class="hiddentext">Footnote </span>38</a></sup>&nbsp;<sup><a href="#footnote39" class="footnote-link"><span class="hiddentext">Footnote </span>39</a></sup>&nbsp;<sup><a href="#footnote40" class="footnote-link"><span class="hiddentext">Footnote </span>40</a></sup>.</p>
        <p><strong>ZOONOSIS</strong>: Zoonosis between humans and animal is suspected <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>&nbsp;<sup><a href="#footnote37" class="footnote-link"><span class="hiddentext">Footnote </span>37</a></sup>.</p>
        <p><strong>VECTORS</strong>: Unknown.</p>
        <h3>SECTION IV - STABILITY AND VIABILITY</h3>
				<p><strong>All information available on stability and  viability comes from peer-reviewed literature sources depicting experimental  findings and is intended to support local risk assessments in a laboratory  setting.</strong></p>
        <p><strong>DRUG SUSCEPTIBILITY</strong>: Unknown. Although clinical trials have been completed, no vaccine has been approved for treatment of ebolavirus. Similarly, no post-exposure measures have been reported as effective in treating ebolavirus infection in humans although several studies have been completed in animals to determine the efficacy of various treatments.</p>
        <p><strong>DRUG RESISTANCE</strong>: There are no known antiviral treatments available for human infections.</p>
        <p><strong>SUSCEPTIBILITY TO DISINFECTANTS</strong>: Ebolavirus is susceptible to 3% acetic acid, 1% glutaraldehyde, alcohol-based products, and dilutions (1:10-1:100 for &ge;10 minutes) of 5.25% household bleach (sodium hypochlorite), and calcium hypochlorite (bleach powder) <sup><a href="#footnote48" class="footnote-link"><span class="hiddentext">Footnote </span>48</a></sup>&nbsp;<sup><a href="#footnote49" class="footnote-link"><span class="hiddentext">Footnote </span>49</a></sup>&nbsp;<sup><a href="#footnote50" class="footnote-link"><span class="hiddentext">Footnote </span>50</a></sup>&nbsp;<sup><a href="#footnote62" class="footnote-link"><span class="hiddentext">Footnote </span>62</a></sup>&nbsp;<sup><a href="#footnote63" class="footnote-link"><span class="hiddentext">Footnote </span>63</a></sup>. The WHO recommendations for cleaning up spills of blood or body fluids suggest flooding the area with a 1:10 dilutions of 5.25% household bleach for 10 minutes for surfaces that can tolerate stronger bleach solutions (e.g., cement, metal) <sup><a href="#footnote62" class="footnote-link"><span class="hiddentext">Footnote </span>62</a></sup>. For surfaces that may corrode or discolour, they recommend careful cleaning to remove visible stains followed by contact with a 1:100 dilution of 5.25% household bleach for more than 10 minutes.</p>
        <p><strong>PHYSICAL INACTIVATION</strong>: Ebola are moderately thermolabile and can be inactivated by heating for 30 minutes to 60 minutes at 60&deg;C, boiling for 5 minutes, or gamma irradiation (1.2 x106 rads to 1.27 x106 rads) combined with 1% glutaraldehyde <sup><a href="#footnote10" class="footnote-link"><span class="hiddentext">Footnote </span>10</a></sup>&nbsp;<sup><a href="#footnote48" class="footnote-link"><span class="hiddentext">Footnote </span>48</a></sup>&nbsp;<sup><a href="#footnote50" class="footnote-link"><span class="hiddentext">Footnote </span>50</a></sup>. Ebolavirus has also been determined to be moderately sensitive to UVC radiation <sup><a href="#footnote51" class="footnote-link"><span class="hiddentext">Footnote </span>51</a></sup>.</p>
        <p><strong>SURVIVAL OUTSIDE HOST</strong>: Filoviruses have been reported capable to survive for weeks in blood and can also survive on contaminated surfaces, particularly at low temperatures (4&deg;C) <sup><a href="#footnote52" class="footnote-link"><span class="hiddentext">Footnote </span>52</a></sup>&nbsp;<sup><a href="#footnote61" class="footnote-link"><span class="hiddentext">Footnote </span>61</a></sup>. One  study could not recover any Ebolavirus from experimentally contaminated  surfaces (plastic, metal or glass) at room temperature <sup><a href="#footnote61" class="footnote-link"><span class="hiddentext">Footnote </span>61</a></sup>. &nbsp;In another study, Ebolavirus  dried onto glass, polymeric silicone rubber, or painted aluminum alloy is able  to survive in the dark for several hours under  ambient conditions (between 20&deg;C and 25&deg;C and 30&ndash;40% relative humidity) (amount of virus reduced to 37%  after 15.4 hours), but is less stable than some other viral hemorrhagic fevers  (Lassa) <sup><a href="#footnote53" class="footnote-link"><span class="hiddentext">Footnote </span>53</a></sup>. When dried in tissue culture media onto glass and stored at 4 &deg;C, Zaire ebolavirus survived for over 50 days <sup><a href="#footnote61" class="footnote-link"><span class="hiddentext">Footnote </span>61</a></sup>. This information is based on experimental findings  only and not based on observations in nature. This information is intended to  be used to support local risk assessments in a laboratory setting.  </p>
				<p>A study on transmission of ebolavirus from fomites  in an isolation ward concludes that the risk of transmission is low when  recommended infection control guidelines for viral hemorrhagic fevers are  followed <sup><a href="#footnote64" class="footnote-link"><span class="hiddentext">Footnote </span>64</a></sup>. Infection control protocols included decontamination  of floors with 0.5% bleach daily and decontamination of visibly contaminated  surfaces with 0.05% bleach as necessary.</p>
        <h3>SECTION V - FIRST AID / MEDICAL</h3>
        <p><strong>SURVEILLANCE</strong>: Definitive  diagnosis can be reached rapidly in an appropriately equipped  laboratory using a multitude of approaches, including RT-PCR to detect viral  RNA, ELISA based techniques to detect anti-Ebola antibodies or viral antigens,  immunoelectron microscopy to detect ebolavirus particles in tissues and cells,  and indirect immunofluorescence to detect antiviral antibodies  <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote14" class="footnote-link"><span class="hiddentext">Footnote </span>14</a></sup>&nbsp;<sup><a href="#footnote41" class="footnote-link"><span class="hiddentext">Footnote </span>41</a></sup>. It is useful to note that the Marburg virus is morphologically indistinguishable from the ebolavirus, and laboratory surveillance of Ebola is extremely hazardous <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote14" class="footnote-link"><span class="hiddentext">Footnote </span>14</a></sup>&nbsp;<sup><a href="#footnote54" class="footnote-link"><span class="hiddentext">Footnote </span>54</a></sup>. Please see the <a href="/id-mi/vhf-fvh/ebola-biosafety-biosecurite-eng.php"><strong>interim biosafety guidelines for laboratories handling specimens from patients under investigation</strong></a> for EVD for more information.</p>
        <p>Note: All diagnostic methods are not necessarily available in all countries.</p>
        <p><strong>FIRST AID/TREATMENT</strong>: There is no effective antiviral treatment <sup><a href="#footnote27" class="footnote-link"><span class="hiddentext">Footnote </span>27</a></sup>&nbsp;<sup><a href="#footnote37" class="footnote-link"><span class="hiddentext">Footnote </span>37</a></sup>. Instead, treatment is supportive, and is directed at maintaining organ function and electrolyte balance and combating haemorrhage and shock <sup><a href="#footnote22" class="footnote-link"><span class="hiddentext">Footnote </span>22</a></sup>&nbsp;<sup><a href="#footnote55" class="footnote-link"><span class="hiddentext">Footnote </span>55</a></sup>.</p>
        <p><strong>IMMUNIZATION</strong>: None <sup><a href="#footnote27" class="footnote-link"><span class="hiddentext">Footnote </span>27</a></sup>.</p>
        <p><strong>PROPHYLAXIS</strong>: None. Management of the Ebola virus is solely based on isolation and barrier-nursing with symptomatic and supportive treatments <sup><a href="#footnote8" class="footnote-link"><span class="hiddentext">Footnote </span>8</a></sup>.</p>
        <h3>SECTION VI - LABORATORY HAZARDS</h3>
        <p><strong>LABORATORY-ACQUIRED INFECTIONS</strong>: One reported near-fatal case following a minute finger prick in an English laboratory (1976) <sup><a href="#footnote56" class="footnote-link"><span class="hiddentext">Footnote </span>56</a></sup>. A Swiss zoologist contracted Ebola virus after performing an autopsy on a chimpanzee in 1994 <sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote57" class="footnote-link"><span class="hiddentext">Footnote </span>57</a></sup>. An incident occurred in Germany in 2009 when a laboratory scientist pricked herself with a needle that had just been used on a mouse infected with Ebola; however, human infection was not confirmed. Additional incidents were recorded in the US in 2004, and a fatal case in Russia in 2004 <sup><a href="#footnote8" class="footnote-link"><span class="hiddentext">Footnote </span>8</a></sup>.</p>
        <p><strong>SOURCES/SPECIMENS</strong>: Blood, serum, urine, respiratory and throat secretions, semen, and organs or their homogenates from human or animal hosts <sup><a href="#footnote1" class="footnote-link"><span class="hiddentext">Footnote </span>1</a></sup>&nbsp;<sup><a href="#footnote2" class="footnote-link"><span class="hiddentext">Footnote </span>2</a></sup>&nbsp;<sup><a href="#footnote53" class="footnote-link"><span class="hiddentext">Footnote </span>53</a></sup>. Human or animal hosts, including non-human primates, may represent a further source of infection <sup><a href="#footnote54" class="footnote-link"><span class="hiddentext">Footnote </span>54</a></sup>.</p>
        <p><strong>PRIMARY HAZARDS</strong>: Accidental parenteral inoculation, respiratory exposure to infectious aerosols/droplets, and/or direct contact with skin or mucous membranes <sup><a href="#footnote54" class="footnote-link"><span class="hiddentext">Footnote </span>54</a></sup>.</p>
        <p><strong>SPECIAL HAZARDS</strong>: Work with, or exposure to, infected non-human primates, rodents, or their carcasses represents a risk of human infection <sup><a href="#footnote54" class="footnote-link"><span class="hiddentext">Footnote </span>54</a></sup>.</p>
        <h3>SECTION VII - EXPOSURE CONTROLS / PERSONAL PROTECTION</h3>
        <p><strong>RISK GROUP CLASSIFICATION</strong>: Risk Group 4 <sup><a href="#footnote58" class="footnote-link"><span class="hiddentext">Footnote </span>58</a></sup>.</p>
        <p><strong>CONTAINMENT REQUIREMENTS</strong>: Containment Level 4 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials, animals, and cultures. Please see the <a href="/id-mi/vhf-fvh/ebola-biosafety-biosecurite-eng.php"><strong>interim biosafety guidelines for laboratories handling specimens from patients under investigation</strong></a> for EVD for more information.</p>
        <p><strong>PROTECTIVE CLOTHING</strong>: Personnel entering the laboratory must remove street clothing, including undergarments, and jewellery, and change into dedicated laboratory clothing and shoes, or don full coverage protective clothing (i.e., completely covering all street clothing). Additional protection may be worn over laboratory clothing when infectious materials are directly handled, such as solid-front gowns with tight fitting wrists, gloves, and respiratory protection. Eye protection must be used where there is a known or potential risk of exposure to splashes.</p>
        <p><strong>OTHER PRECAUTIONS</strong>: All activities with infectious material should be conducted in a biological safety cabinet (BSC) in combination with a positive pressure suit, or within a class III BSC line. Centrifugation of infected materials must be carried out in closed containers placed in sealed safety cups, or in rotors that are unloaded in a biological safety cabinet. The integrity of positive pressure suits must be routinely checked for leaks. The use of needles, syringes, and other sharp objects should be strictly limited. Open wounds, cuts, scratches, and grazes should be covered with waterproof dressings. Additional precautions should be considered with work involving animal activities.</p>
        <h3>SECTION VIII - HANDLING AND STORAGE</h3>
        <p><strong>SPILLS</strong>: Allow aerosols to settle and, wearing protective clothing, gently cover spill with paper towels and apply suitable disinfectant, starting at the perimeter and working towards the centre. Allow sufficient contact time before clean-up.</p>
        <p><strong>DISPOSAL</strong>: Decontaminate all materials for disposal from the containment laboratory by steam sterilisation, chemical disinfection, incineration or by gaseous methods. Contaminated materials include both liquid and solid wastes.</p>
        <p><strong>STORAGE</strong>: In sealed, leak-proof containers that are appropriately labelled and locked in a Containment Level 4 laboratory.</p>
        <h3>SECTION IX - REGULATORY AND OTHER INFORMATION</h3>
        <p><strong>REGULATORY INFORMATION</strong>: The import, transport, and use of pathogens in Canada is regulated under many regulatory bodies, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment Canada, and Transport Canada. Users are responsible for ensuring they are compliant with all relevant acts, regulations, guidelines, and standards.</p>
        <p><strong>UPDATED</strong>: August 2014.</p>
        <p><strong>PREPARED BY</strong>: Centre for Biosecurity, Public Health Agency of Canada.</p>
        <p>Although the information, opinions and recommendations contained in this Pathogen Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.</p>
        <p>Copyright &copy;</p>
        <p>Public Health Agency of Canada, 2014<br />
          Canada</p>
        <h2>REFERENCES</h2>
        <dl class="footnotes-list">
          <dt id="footnote1"><span class="hiddentext">Footnote </span>1</dt>
          <dd>Plague. (2004). In R. G. Darling, &amp; J. B. Woods (Eds.), USAMRIID's Medical Management of Biological Casualties Handbook (5th ed., pp. 40-44). Fort Detrick M.D.: USAMRIID.</dd>
          <dt id="footnote2"><span class="hiddentext">Footnote </span>2</dt>
          <dd>Acha, P. N., &amp; Szyfres, B. (2003). In Pan American Health Organization (Ed.), Zoonoses and Communicable Diseases Common to Man and Animals (3rd ed., pp. 142-145). Washington D.C.: Pan American Health Organization.</dd>
          <dt id="footnote3"><span class="hiddentext">Footnote </span>3</dt>
          <dd>International Committee on Taxonomy of Viruses (2013 Release). Virus Taxonomy. Ebolavirus. http://www.ictvonline.org/virusTaxonomy.asp</dd>
          <dt id="footnote4"><span class="hiddentext">Footnote </span>4</dt>
          <dd>Kuhn, J. H., Becker, S., Ebihara, H., Geisbert, T. W., Johnson, K. M., Kawaoka, Y., Lipkin IW, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchokov VE, &amp; Jahrling, P. B. (2010). Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Archives of virology, 155(12), 2083-2103.</dd>
          <dt id="footnote5"><span class="hiddentext">Footnote </span>5</dt>
          <dd>Sanchez, A. (2001). Filoviridae: Marburg and Ebola Viruses. In D. M. Knipe, &amp; P. M. Howley (Eds.), Fields virology (4th ed., pp. 1279-1304). Philadelphia, PA.: Lippencott-Ravenpp.</dd>
          <dt id="footnote6"><span class="hiddentext">Footnote </span>6</dt>
          <dd>Takada, A., &amp; Kawaoka, Y. (2001). The pathogenesis of Ebola hemorrhagic fever. Trends in Microbiology, 9(10), 506-511.</dd>
          <dt id="footnote7"><span class="hiddentext">Footnote </span>7</dt>
          <dd>Towner, J. S., Sealy, T. K., Khristova, M. L., Albarino, C. G., Conlan, S., Reeder, S. A., Quan, P. L., Lipkin, W. I., Downing, R., Tappero, J. W., Okware, S., Lutwama, J., Bakamutumaho, B., Kayiwa, J., Comer, J. A., Rollin, P. E., Ksiazek, T. G., &amp; Nichol, S. T. (2008). Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens, 4(11), e1000212.</dd>
          <dt id="footnote8"><span class="hiddentext">Footnote </span>8</dt>
          <dd>Feldmann, H. (2010). Are we any closer to combating Ebola infections? Lancet, 375(9729), 1850-1852. doi:10.1016/S0140-6736(10)60597-1.</dd>
          <dt id="footnote9"><span class="hiddentext">Footnote </span>9</dt>
          <dd>Beran, G. W. (Ed.). (1994). Handbook of Zoonosis, Section B: Viral (2nd ed.). Boca Raton, Florida: CRC Press, LLC.</dd>
          <dt id="footnote10"><span class="hiddentext">Footnote </span>10</dt>
          <dd>Mwanatambwe, M., Yamada, N., Arai, S., Shimizu-Suganuma, M., Shichinohe, K., &amp; Asano, G. (2001). Ebola hemorrhagic fever (EHF): mechanism of transmission and pathogenicity. Journal of Nippon Medical School.68(5), 370-375.</dd>
          <dt id="footnote11"><span class="hiddentext">Footnote </span>11</dt>
          <dd>Sanchez, A., Kiley, M. P., Klenk, H. D., &amp; Feldmann, H. (1992). Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. The Journal of General Virology, 73 (Pt 2)(Pt 2), 347-357.</dd>
          <dt id="footnote12"><span class="hiddentext">Footnote </span>12</dt>
          <dd>Harcourt, B. H., Sanchez, A., &amp; Offermann, M. K. (1999). Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. Journal of Virology, 73(4), 3491-3496.</dd>
          <dt id="footnote13"><span class="hiddentext">Footnote </span>13</dt>
          <dd>Bwaka, M. A., Bonnet, M. J., Calain, P., Colebunders, R., De Roo, A., Guimard, Y., Katwiki, K. R., Kibadi, K., Kipasa, M. A., Kuvula, K. J., Mapanda, B. B., Massamba, M., Mupapa, K. D., Muyembe-Tamfum, J. J., Ndaberey, E., Peters, C. J., Rollin, P. E., Van den Enden, E., &amp; Van den Enden, E. (1999). Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. The Journal of Infectious Diseases, 179 Suppl 1, S1-7.</dd>
          <dt id="footnote14"><span class="hiddentext">Footnote </span>14</dt>
          <dd>Zilinskas, R. A. (Ed.). (2000). Biololgical Warfare - Modern Offense and Defense. Boulder, Colorado, USA: Lynne Rienner Publishers, Inc.</dd>
          <dt id="footnote15"><span class="hiddentext">Footnote </span>15</dt>
          <dd>Feigin, R. D. (Ed.). (2004). Textbook of Pediatric Infectious Diseases (5th ed.). Philadelphia, USA: Elsevier, Inc.</dd>
          <dt id="footnote16"><span class="hiddentext">Footnote </span>16</dt>
          <dd>Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M. S., Keita, S., De Clerck, H., Tiffany, A., Dominguez, G., Loua, M., Traore, A., Kolie, M., Malano, E. R., Heleze, E., Bocquin, A., Mely, S., Raoul, H., Caro, V., Cadar, D., Gabriel, M., Pahlmann, M., Tappe, D., Schmidt-Chanasit, J., Impouma, B., Diallo, A.K., Formenty, P., Van Herp, M., &amp; Gunther, S. (2014). Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. The New England Journal of Medicine. Epub ahead of print.</dd>
          <dt id="footnote17"><span class="hiddentext">Footnote </span>17</dt>
          <dd>Casillas, A. M., Nyamathi, A. M., Sosa, A., Wilder, C. L., &amp; Sands, H. (2003). A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biological Research for Nursing, 4(4), 268-275.</dd>
          <dt id="footnote18"><span class="hiddentext">Footnote </span>18</dt>
          <dd>World Health Organization. Ebola Virus Disease - Fact Sheet N&deg;103. Updated April 2014.</dd>
          <dt id="footnote19"><span class="hiddentext">Footnote </span>19</dt>
          <dd>Centers for Disease Control and Prevention. (1990). Epidemiologic notes and reports updates: filovirus infection in animal handlers. MMWR, 39, 221.</dd>
          <dt id="footnote20"><span class="hiddentext">Footnote </span>20</dt>
          <dd>World Health Organization. Global Alert and Response (GAR) - Ebola virus disease update - West Africa. Disease outbreak news. August 6 2014</dd>
          <dt id="footnote21"><span class="hiddentext">Footnote </span>21</dt>
          <dd>Centres for Disease Control. 2014 Ebola Outbreak in West Africa (Guinea, Liberia, Sierra Leone and Nigeria. August 6 2014</dd>
          <dt id="footnote22"><span class="hiddentext">Footnote </span>22</dt>
          <dd>Bausch, D. G., Jeffs B.S.A.G, &amp; Boumandouki, P. (2008). Treatment of Marburg and Ebola haemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res., 78(1), 150-161.</dd>
          <dt id="footnote23"><span class="hiddentext">Footnote </span>23</dt>
          <dd>WHO Disease Outbreak News - Ebola Haemorrhagic Fever in the Democratic Republic of Congo. (2007). 2008</dd>
          <dt id="footnote24"><span class="hiddentext">Footnote </span>24</dt>
          <dd>WHO Disease Outbreak News - Ebola Haemorrhagic Fever in Uganda - Update. (2007). 2008</dd>
          <dt id="footnote25"><span class="hiddentext">Footnote </span>25</dt>
          <dd>Formenty, P., Boesch, C., Wyers, M., Steiner, C., Donati, F., Dind, F., Walker, F., &amp; Le Guenno, B. (1999). Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire. The Journal of Infectious Diseases, 179 Suppl 1, S120-6. doi:10.1086/514296.</dd>
          <dt id="footnote26"><span class="hiddentext">Footnote </span>26</dt>
          <dd>Bray, M. (2003). Defense against filoviruses used as biological weapons. Antiviral Research, 57(1-2), 53-60.</dd>
          <dt id="footnote27"><span class="hiddentext">Footnote </span>27</dt>
          <dd>Leroy, E. M., Rouquet, P., Formenty, P., Souqui&egrave;re, S., Kilbourne, A., Froment, J., Bermejo, M., Smit, S., Karesh, W., Swanepoel, R., Zaki, S. R., &amp; Rollin, P. E. (2004). Multiple Ebola Virus Transmission Events and Rapid Decline of Central African Wildlife. Science, 303(5656), 387-390.</dd>
          <dt id="footnote28"><span class="hiddentext">Footnote </span>28</dt>
          <dd>Nfon, C. K., Leung, A., Smith, G., Embury-Hyatt, C., Kobinger, G., &amp; Weingartl, H. M. (2013). Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs. PloS one, 8(4), e61904.</dd>
          <dt id="footnote29"><span class="hiddentext">Footnote </span>29</dt>
          <dd>Kobinger, G. P., Leung, A., Neufeld, J., Richardson, J. S., Falzarano, D., Smith, G., Tierney, K., Patel, A., &amp; Weingartl, H. M. (2011). Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. Journal of Infectious Diseases, jir077.</dd>
          <dt id="footnote30"><span class="hiddentext">Footnote </span>30</dt>
          <dd>Marsh, G. A., Haining, J., Robinson, R., Foord, A., Yamada, M., Barr, J. A., Payne, J., White, J., Yu, M., Bingham, J., Rollin, P. E., Nichol, S. T., Wang, L-F., &amp; Middleton, D. (2011). Ebola Reston virus infection of pigs: clinical significance and transmission potential. Journal of Infectious Diseases, 204(suppl 3), S804-S809.</dd>
          <dt id="footnote31"><span class="hiddentext">Footnote </span>31</dt>
          <dd>Morris, K. (2009). First pig-to-human transmission of Ebola Reston virus.9(3), 148.</dd>
          <dt id="footnote32"><span class="hiddentext">Footnote </span>32</dt>
          <dd>Allela, L., Bourry, O., Pouillot, R., D&eacute;licat, A., Yaba, P., Kumulungui, B., Rougquet, P., Gonzalez, J-P., &amp; Leroy, E. M. (2005). Ebola virus antibody prevalence in dogs and human risk. Emerg Infect Dis, 11(3), 385-90.</dd>
          <dt id="footnote33"><span class="hiddentext">Footnote </span>33</dt>
          <dd>Olson, S. H., Reed, P., Cameron, K. N., Ssebide, B. J., Johnson, C. K., Morse, S. S., Karesh, W. B.., Mazet, J. A. K., &amp; Joly, D. O. (2012). Dead or alive: animal sampling during Ebola hemorrhagic fever outbreaks in humans. Emerging health threats journal, 5.</dd>
          <dt id="footnote34"><span class="hiddentext">Footnote </span>34</dt>
          <dd>Morvan, J. M., Nakoun&eacute;, E., Deubel, V., &amp; Colyn, M. (2000). Ebola virus and forest ecosystem. [&Eacute;cosyst&egrave;mes forestiers et virus Ebola] Bulletin De La Societe De Pathologie Exotique, 93(3), 172-175.</dd>
          <dt id="footnote35"><span class="hiddentext">Footnote </span>35</dt>
          <dd>Connolly, B. M., Steele, K. E., Davis, K. J., Geisbert, T. W., Kell, W. M., Jaax, N. K., &amp; Jahrling, P. B. (1999). Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of Infectious Diseases, 179 Suppl 1, S203-17.</dd>
          <dt id="footnote36"><span class="hiddentext">Footnote </span>36</dt>
          <dd>Ebihara, H., Zivcec, M., Gardner, D., Falzarano, D., LaCasse, R., Rosenke, R., Long, D., Haddock, E., Fischer, E., Kawaoka, Y., &amp; Feldmann, H. (2012). A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. Journal of Infectious Diseases, jis626.</dd>
          <dt id="footnote37"><span class="hiddentext">Footnote </span>37</dt>
          <dd>Leroy, E. M., Kumulungui, B., Pourrut, X., Rouquet, P., Hassanin, A., Yaba, P., D&eacute;licat, A., Paweska, J. T., Gonzalez, J., &amp; Swanepoel, R. (2005). Fruit bats as reservoirs of Ebola virus. Nature, 438(7068), 575-576.</dd>
          <dt id="footnote38"><span class="hiddentext">Footnote </span>38</dt>
          <dd>Hayman, D. T., Yu, M., Crameri, G., Wang, L. F., Suu-Ire, R., Wood, J. L., &amp; Cunningham, A. A. (2012). Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerging infectious diseases, 18(7), 1207.</dd>
          <dt id="footnote39"><span class="hiddentext">Footnote </span>39</dt>
          <dd>Yuan, J., Zhang, Y., Li, J., Zhang, Y., Wang, L. F., &amp; Shi, Z. (2012). Serological evidence of ebolavirus infection in bats, China. Virol. J, 9, 236.</dd>
          <dt id="footnote40"><span class="hiddentext">Footnote </span>40</dt>
          <dd>Olival, K. J., Islam, A., Yu, M., Anthony, S. J., Epstein, J. H., Khan, S. A., Khan, S. U., Crameri, G., Wang, L-F., Lipkin, W. I., Luby, S. P., &amp; Daszak, P. (2013). Ebola virus antibodies in fruit bats, Bangladesh. Emerging infectious diseases, 19(2), 270.</dd>
          <dt id="footnote41"><span class="hiddentext">Footnote </span>41</dt>
          <dd>Franz, D. R., Jahrling, P. B., Friedlander, A. M., McClain, D. J., Hoover, D. L., Bryne, W. R., Pavlin, J. A., Christopher, G. W., &amp; Eitzen, E. M. (1997). Clinical recognition and management of patients exposed to biological warfare agents. Jama, 278(5), 399-411.</dd>
          <dt id="footnote42"><span class="hiddentext">Footnote </span>42</dt>
          <dd>Arthur, R. R. (2002). Ebola in Africa--discoveries in the past decade. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 7(3), 33-36.</dd>
          <dt id="footnote43"><span class="hiddentext">Footnote </span>43</dt>
          <dd>Hewlett, B. S., &amp; Amolat, R. P. (2003). Cultural contexts of Ebola in Northern Uganda. Emerging Infectious Diseases, 9(10), 1242-1248.</dd>
          <dt id="footnote44"><span class="hiddentext">Footnote </span>44</dt>
          <dd>Reed, D. S., Lackemeyer, M. G., Garza, N. L., Sullivan, L. J., &amp; Nichols, D. K. (2011). Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes and Infection, 13(11), 930-936.</dd>
          <dt id="footnote45"><span class="hiddentext">Footnote </span>45</dt>
          <dd>Twenhafel, N. A., Mattix, M. E., Johnson, J. C., Robinson, C. G., Pratt, W. D., Cashman, K. A., Wahl-Jensen, V., Terry, C., Olinger, G. G., Hensley, L. E., &amp; Honko, A. N. (2012). Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Veterinary Pathology Online, 0300985812469636.</dd>
          <dt id="footnote46"><span class="hiddentext">Footnote </span>46</dt>
          <dd>Weingartl, H. M., Embury-Hyatt, C., Nfon, C., Leung, A., Smith, G., &amp; Kobinger, G. (2012). Transmission of Ebola virus from pigs to non-human primates. Scientific reports, 2.</dd>
          <dt id="footnote47"><span class="hiddentext">Footnote </span>47</dt>
          <dd>Stansfield, S. K., Scribner, C. L., Kaminski, R. M., Cairns, T., McCormick, J. B., &amp; Johnson, K. M. (1982). Antibody to Ebola virus in guinea pigs: Tandala, Zaire. The Journal of Infectious Diseases, 146(4), 483-486.</dd>
          <dt id="footnote48"><span class="hiddentext">Footnote </span>48</dt>
          <dd>Mitchell, S. W., &amp; McCormick, J. B. (1984). Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. Journal of Clinical Microbiology, 20(3), 486-489.</dd>
          <dt id="footnote49"><span class="hiddentext">Footnote </span>49</dt>
          <dd>Elliott, L. H., McCormick, J. B., &amp; Johnson, K. M. (1982). Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. Journal of Clinical Microbiology, 16(4), 704-708.</dd>
          <dt id="footnote50"><span class="hiddentext">Footnote </span>50</dt>
          <dd>World Health Organization. Interim Infection Control Recommendationsfor Care of Patients with Suspected or Confirmed Filovirus (Ebola, Marburg) Haemorrhagic Fever. March 2008</dd>
          <dt id="footnote51"><span class="hiddentext">Footnote </span>51</dt>
          <dd>Sagripanti, J. L., &amp; Lytle, C. D. (2011). Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Archives of virology, 156(3), 489-494.</dd>
          <dt id="footnote52"><span class="hiddentext">Footnote </span>52</dt>
          <dd>Belanov, E. F., Muntianov, V. P., Kriuk, V., Sokolov, A. V., Bormotov, N. I., P'iankov, O. V., &amp; Sergeev, A. N. (1995). [Survival of Marburg virus infectivity on contaminated surfaces and in aerosols]. Voprosy virusologii, 41(1), 32-34.</dd>
          <dt id="footnote53"><span class="hiddentext">Footnote </span>53</dt>
          <dd>Sagripanti, J-L., Rom, A.M., Holland, L.E. (2010) Persistence in darkness of virulent alphaviruses, Ebola virus, and Lass virus deposited on solid surfaces. Arch Virol. 155: 2035-9.</dd>
          <dt id="footnote54"><span class="hiddentext">Footnote </span>54</dt>
          <dd>Biosafety in Microbiological and Biomedical Laboratories (BMBL) (2007). In Richmond J. Y., McKinney R. W. (Eds.), . Washington, D.C.: Centers for Disease Control and Prevention.</dd>
          <dt id="footnote55"><span class="hiddentext">Footnote </span>55</dt>
          <dd>Clark, D. V., Jahrling, P. B., &amp; Lawler, J. V. (2012). Clinical Management of Filovirus-Infected Patients. Viruses, 4(9), 1668-1686.</dd>
          <dt id="footnote56"><span class="hiddentext">Footnote </span>56</dt>
          <dd>Emond, R. T. D., Evans, B., Bowen, E. T. W., &amp; Lloyd, G. (1977). A case of Ebola virus infection. British Medical Journal, 2(6086), 541-544.</dd>
          <dt id="footnote57"><span class="hiddentext">Footnote </span>57</dt>
          <dd>Formenty, P., Hatz, C., Le Guenno, B., Stoll, A., Rogenmoser, P., &amp; Widmer, A. (1999). Human infection due to Ebola virus, subtype Cote d'Ivoire: Clinical and biologic presentation. Journal of Infectious Diseases, 179(SUPPL. 1), S48-S53.</dd>
          <dt id="footnote58"><span class="hiddentext">Footnote </span>58</dt>
          <dd>Human pathogens and toxins act. S.C. 2009, c. 24, Second Session, Fortieth Parliament, 57-58 Elizabeth II, 2009. (2009).</dd>
          <dt id="footnote59"><span class="hiddentext">Footnote </span>59</dt>
          <dd>Rowe AK, Bertolli J,Khan AS,et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies &agrave; Kikwit. J Infect Dis 1999;179 (Suppl 1):S28-35.</dd>
          <dt id="footnote60"><span class="hiddentext">Footnote </span>60</dt>
          <dd>Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179 (Suppl 1):S170-6.</dd>
          <dt id="footnote61"><span class="hiddentext">Footnote </span>61</dt>
          <dd>Piercy, T.J., Smither, S.J., Steward, J.A., Eastaugh, L., Lever, M.S. (2010) The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol. 109(5): 1531-9.</dd>
          <dt id="footnote62"><span class="hiddentext">Footnote </span>62</dt>
          <dd>World Health Organization (2010). WHO best practices for injections and related procedures toolkit. March 2010. http://whqlibdoc.who.int/publications/2010/9789241599252_eng.pdf?ua=1</dd>
          <dt id="footnote63"><span class="hiddentext">Footnote </span>63</dt>
          <dd>World Health Organization (2014). Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola. August 2014.<br />
http://www.who.int/csr/resources/who-ipc-guidance-ebolafinal-09082014.pdf</dd>
					<dt id="footnote64"><span class="hiddentext">Footnote </span>64</dt>
          <dd>Baush,  D.G., Towner, J.S., Dowell, S.F., Kaducu, F., Lukwiya, M., Sanchez, A., Nichol,  S.T., Ksiazek, T.G., Rollin, P.E. (2007) Assessment of the Risk of Ebola virus  Transmission from Bodily Fluids and Fomites. JID. 196 (Suppl 2).</dd>
        </dl>
        <!-- InstanceEndEditable --></div>
      <!-- CONTENT ENDS | FIN DU CONTENU -->
      <!-- TWO COLUMN LAYOUT ENDS | FIN DE LA MISE EN PAGE DE DEUX COLONNES -->
         <!-- FOOTER BEGINS | DEBUT DU PIED DE LA PAGE -->
   <div class="footer">
    <div class="footerline"></div>
    <div class="foot1">
     <!-- DATE MODIFIED BEGINS | DEBUT DE LA DATE DE MODIFICATION -->
     Date Modified: <span class="date"> 2014-08-22 </span>
     <!-- DATE MODIFIED ENDS | FIN DE LA DATE DE MODIFICATION -->
    </div>
    <div class="foot2">
		<a class="nav" href="#tphp" title="Return to Top of Page"><img class="uparrow" src="/images/tphp.gif" width="19" height="12" alt="" /><br />
     	Top of Page</a>
	</div>
    <div class="foot3"><a href="/im-ai-eng.php">Terms and Conditions</a></div>
   </div>
  <!-- FOOTER ENDS | FIN DU PIED DE LA PAGE -->    </div>
  </div>
</div>
</body>
<!-- InstanceEnd -->
</html>
